G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation

Japanese Journal of Cancer Research

Volumn 90, Issue 12, 1999, Pages 1364-1372

  Akiyama, Tadakazu ^a   Sugiyama, Kazuyo ^a   Shimizu, Makiko ^a   Tamaoki, Tatsuya ^a   Akinaga, Shiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

7 Hydroxystaurosporine (UCN 01); Apoptosis; Cyclin dependent kinase 2; G1 checkpoint; G1 phase accumulation

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL SURVIVAL; CELL TRANSFORMATION; COLON CARCINOMA; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SIMIAN VIRUS 40;

EID: 0033389155     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00721.x     Document Type: Article

References (39)

1. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M. and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot. (Tokyo), 40, 1782-1784 (1987).
2. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T. and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51, 4888-4892 (1991).
3. Akinaga, S., Nomura, K., Gomi, K. and Okabe, M. Synergistic antitumor effect of UCN-01, a protein kinase C inhibitor, combined with various anticancer agents. Proc. Am. Assoc. Cancer Res., 33, 514 (1992).
4. Akinaga, S., Nomura, K., Gomi, K. and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32, 183-189 (1993).
5. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E. and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343-349 (1997).
6. 1-acid glycoprotein. Cancer Res., 58, 3248-3253 (1998).
7. Sausville, E. A., Lush, R. D., Headlee, D., Smith, A. C., Figg, W. D., Arbuck, S. G., Senderowicz, A. M., Fuse, E., Tanii, H., Kuwabara, T. and Kobayashi, S. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother. Pharmacol., 42, S54-S59 (1998).
8. MacLachlan, T. K., Sang, N. and Giordano, A. Cyclins, cyclin-dependent kinases and CDK inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr., 5, 127-156 (1995).
9. Sherr, C. J. Cancer cell cycles. Science, 274, 1672-1677 (1996).
10. Manfredi, J. J. and Prives, C. The transforming activity of simian virus 40 large tumor antigen. Biochim. Biophys. Acta, 1198, 65-83 (1994).
11. Ludlow, J. W. and Skuse, G. R. Viral oncoprotein binding to pRB, p107, p130, and p300. Virus Res., 35, 113-121 (1995).
12. Stewart, B. W. Mechanisms of apoptosis: integration of genetic biochemical, and cellular indicators. J. Natl. Cancer Inst., 86, 1286-1296 (1994).
13. Villa, P., Kaufmann, S. H. and Earnshaw, W. C. Caspases and caspase inhibitors. Trends Biochem. Sci., 22, 388-393 (1997).
14. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A. and Worland, P. J. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53, 2081-2086 (1993).
15. Akinaga, S., Nomura, K., Gomi, K. and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol., 33, 273-280 (1994).
16. Kawakami, K., Futami, H., Takahara, J. and Yamaguchi, K. UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinase and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung carcinoma cell line. Biochem. Biophys. Res. Commun., 219, 778-783 (1996).
17. Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M. and Akinaga, S. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdil in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57, 1495-1501 (1997).
18. Wang, Q., Worland, P. J., Clark. J. L., Carlson, B. A. and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinase 1 and 2. Cell Growth Differ., 6, 927-936 (1995).
19. Shao, R. G., Shimizu, T. and Pommier, Y. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp. Cell Res., 234, 388-397 (1997).
20. Harkin, S. T., Cohen, G. M. and Gescher, A. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Mol. Pharmacol., 54, 663-670 (1998).
21. Takahashi, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M. and Tamaoki, T. UCN-01 and UCN-02, a new selective inhibitors of protein kinase C. II. Purification, physiochemical properties, structural determinations, and biological activities. J. Antibiot. (Tokyo). 42, 571-576 (1989).
22. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Mitchell, J. B. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936-942 (1987).
23. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
24. Gavrieli, Y., Sherman, Y. and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119, 493-501 (1992).
25. Puisieux, A., Galvin, K., Troalen, F., Bressac. B., Marcais, C., Galun, E., Ponchel, F., Yakicier, C., Ji, J. and Ozturk, M. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J., 7, 1407-1413 (1993).
26. Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V. and Lane. D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA. 87, 7555-7559 (1990).
27. Waldman, T., Kinzler, K. W. and Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55, 5187-5190 (1995).
28. Rieger, K. M., Little, A. F., Swart, J. M., Kastrinakis, W. V., Fitzgerald, J. M., Hess. D. T., Libertino, J. A. and Summerhayes, I. C. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br. J. Cancer, 72, 683-690 (1995).
29. Diller, L., Kassel, J., Nelson, C. E., Gryka. M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B. and Friend, S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol., 10, 5772-5781 (1994).
30. Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I. and Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 51, 4090-4096 (1991).
31. Horowitz, J. M., Park, S. H., Bogenmann, E., Cheng, J. C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P. and Weinberg, R. A. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad Sci. USA, 87, 2775-2779 (1990).
32. Shew, J. Y., Lin, B. T. Y., Chen, P. L. Tseng, B. Y., Yang-Feng, T. L. and Lee, W. H. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc. Natl. Acad Sci. USA, 87, 6-10 (1990).
33. Chen, W. D., Otterson, G. A., Lipkowitz, S., Khleif, S., Coxon, A. B. and Kaye, F. J. Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene, 14, 1243-1248 (1997).
34. Aprelikova, O., Xiong, Y. and Liu, E. T. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem., 270, 18195-18197 (1995).
35. Lloyd, R. V., Erickson, L. A., Jin, L., Kulig, E., Qian, X., Cheville, J. C. and Scheithauer, B. W. p27: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol., 154, 313-323 (1999).
36. Poon, R. Y. C., Toyoshima, H. and Hunter, T. Redistribution of CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell, 6, 1197-1213 (1995).
37. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev., 11, 492-503 (1997).
38. Sugiyama, K., Akiyama, T., Shimizu, M., Tamaoki, T., Courage, C., Gescher, A. and Akinaga, S. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against antisignaling drug UCN-01 (7-hydroxystaurosporine). Cancer Res., 59, 4406-4412 (1999).
39. Levkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K., Roberts, J. M. and Ross, R. Cleavage of p21Cip1/Waf1 and p27Kipl mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. Mol. Cell. 1, 553-563 (1998).